Prosecution Insights
Last updated: November 15, 2026
Application No. 18/955,480

NUCLEIC ACID MOLECULES ENCODING DNA MODIFYING ENZYMES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND COMPOSITIONS COMPRISING THE SAME

Non-Final OA §112
Filed
Nov 21, 2024
Priority
Sep 11, 2020 — provisional 63/077,089 +5 more
Examiner
RAMIREZ, DELIA M
Art Unit
1652
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Life Edit Therapeutics Inc.
OA Round
1 (Non-Final)
65%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
558 granted / 857 resolved
+5.1% vs TC avg
Strong +56% interview lift
Without
With
+56.3%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
50 currently pending
Career history
910
Total Applications
across all art units

Office Action

§112
DETAILED ACTION Status of the Application Claims 1-20 are pending. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s election of Group 1, claims 1-19, drawn in part to a method for modifying a target DNA molecule using a system that comprises a fusion protein that comprises a nickase and deaminase, as submitted in a communication filed on 10/14/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). Claim 20 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 10/14/2026. Claims 1-19 are at issue and will be examined to the extent they encompass the elected invention. Specification The first paragraph of the specification is objected to because it does not provide the current status of related applications (e.g., now US Patent No. X). Appropriate correction is required. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. The claims under consideration are directed to a method. Appropriate correction is required. Priority Acknowledgment is made of a claim for domestic priority under 35 U.S.C. 119(e) to provisional application No. 63/146,840 filed on 02/08/2021, and 63/077,089 filed on 09/11/2020. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. 120 or 121 to PCT/US2021/049853 filed on 09/10/2021, US application No. 17/851,880 filed on 06/28/2022, US application No. 17/929,162 filed on 09/01/2022, and US application No. 18/623,704 filed on 04/01/2024. Upon a cursory review, it appears that SEQ ID NO: 407 and SEQ ID NO: 496 were first disclosed in provisional application 63/146,840 filed on 02/08/2021 (page 189, LPG50148; page 207, LPG50148-nAPG07433.1). Information Disclosure Statement The information disclosure statements (IDS) submitted on 11/21/2024 and 8/20/2026 are acknowledged. The submissions are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. Claim Rejections - 35 USC § 112(b) or Second Paragraph (pre-AIA ) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 1 (claims 2-19 dependent thereon) is indefinite in the recitation of “method for modifying a target DNA molecule, said method comprising delivery a system comprising…” for the following reasons. While the preamble of the claim states that the method is a method for modifying a target DNA molecule, there is no positive step recited indicating how delivering a system would lead to a modified target DNA molecule. Therefore, the claim omits essential steps. In addition, it is unclear as to where is the system delivered to. Correction is required. Claim 1 (claims 2-19 dependent thereon) is indefinite in the recitation of “b) one or more guide RNAs capable of hybridizing to said target DNA molecule or one or more nucleotide sequences encoding the one or more gRNAs; to said target DNA molecule or a cell comprising the target DNA molecule…” for the following reasons. While nucleic acids comprise nucleotide sequences, it is unclear as to how a system can comprise a nucleotide sequence encoding one or more gRNAs. If the intended limitation is a system that comprises one or more guide RNAs or nucleic acids encoding one or more guide RNAs, the claim should be amended accordingly. In addition, it is completely unclear as to how the term “to said target DNA molecule or a cell comprising the target DNA molecule” further limits the claim. Correction is required. Claim 2 is indefinite in the recitation of “wherein said modified target DNA molecule comprises an A>N mutation of at least one nucleotide within the target DNA molecule, wherein N is….” for the following reasons. As written, it is unclear if as a result of the method, a target DNA molecule has an A mutated to an N or if the target DNA molecule has an N in a position that would normally have an A prior to the modification. For examination purposes, claim 2 will be interpreted as a duplicate of claim 1. Correction is required. Claim 3 is indefinite in the recitation of “wherein said modified target DNA molecule comprises an A>G mutation of at least one nucleotide within the target DNA molecule” for the following reasons. As written, it is unclear if as a result of the method, a target DNA molecule has an A mutated to a G or if the target DNA molecule has a G in a position that would normally have an A prior to the modification. For examination purposes, claim 3 will be interpreted as a duplicate of claim 1. Correction is required. Claim 10 is indefinite in the recitation of “wherein at least one of said one or more nucleotide sequences encoding…is operably linked to a promoter” for the following reasons. A sequence is a graphical representation of the order in which nucleotides are arranged in a polynucleotide. A promoter is a nucleic acid. Therefore, it is unclear as to how a sequence can be operably linked to a promoter. If the intended limitation is a nucleic acid encoding a gRNA operably linked to a promoter, the claim should be amended accordingly. Correction is required. Claim 14 (claim 15 dependent thereon) is indefinite in the recitation of “wherein said method comprises viral vector delivery” for the following reasons. It is unclear if the method requires a step where something is delivered via a viral vector. It is noted that the system comprises a protein. Therefore, if the intended limitation is delivering the system using a viral vector, it is unclear as to how a protein can be delivered with a viral vector. For examination purposes, claim 14 will be interpreted as a duplicate of claim 1. Correction is required. Clam 16 (claim 17 dependent thereon) is indefinite in the recitation of “wherein said method comprises lipid particle delivery” for the following reasons. It is unclear if the method requires a step where something is delivered via a lipid particle. If the intended limitation is delivering the system via a lipid particle, the claim should be amended accordingly. For examination purposes, claim 16 will be interpreted as a duplicate of claim 1. Correction is required. When amending the claims, applicant is advised to carefully review all examined claims and make the necessary changes to ensure proper antecedent basis and dependency. Claim Rejections - 35 USC § 112(a) or First Paragraph (pre-AIA ) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-19 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. As stated in MPEP 2111.01, during examination, the claims must be interpreted as broadly as their terms reasonably allow. Claims 1-19 are directed in part to in vivo, in vitro or ex vitro method to modify a target DNA molecule, wherein said method comprises contacting a target DNA molecule with (i) a fusion protein that comprises an adenine deaminase that comprises SEQ ID NO: 407 and a Cas9 nickase that comprises one of SEQ ID NO: 42, 52, 53, 55-59, 61, 397 or 398, and (ii) a guide RNA that is able to hybridize to the target DNA molecule and binds to the fusion protein to comprise a complex, wherein said contacting results in the replacement of an A in the target DNA molecule with any base, thus modifying said target DNA molecule. Please note that the target DNA molecule is not required to be in an isolated cell. Therefore, the target DNA molecule can be part of a multicellular organism, like a human. Also, it is noted that the method requires mutating an adenine to any base and not just guanine See Claim Rejections - 35 USC § 112(b) or Second Paragraph (pre-AIA ) for claim interpretation. In University of California v. Eli Lilly & Co., 43 USPQ2d 1938, the Court of Appeals for the Federal Circuit has held that “A written description of an invention involving a chemical genus, like a description of a chemical species, ‘requires a precise definition, such as by structure, formula, [or] chemical name,’ of the claimed subject matter sufficient to distinguish it from other materials”. As indicated in MPEP § 2163, the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show that Applicant was in possession of the claimed genus. In addition, MPEP § 2163 states that a representative number of species means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The claims as written encompass an in vivo method for base editing a target DNA molecule by introducing into a multicellular organism, such as a human being, a fusion protein that comprises an adenine deaminase that comprises SEQ ID NO: 407 and a Cas9 nickase that comprises one of SEQ ID NO: 42, 52, 53, 55-59, 61, 397 or 398, and a guide RNA that is able to hybridize to the target DNA molecule and binds to the fusion protein to comprise a complex. Moreover, the claims as written encompass an in vivo, in vitro and ex vivo method where an alanine is substituted with any nucleotide (i.e., C, G, or T). While the specification discloses that the protein of SEQ ID NO: 407 can edit an A to a G, the specification is silent with regard to those modifications that can be made to the protein of SEQ ID NO: 407 to obtain a variant having at least 90% sequence identity to the polypeptide of SEQ ID NO: 407 which is able to edit an A to C or T. In addition, while the specification discloses an in vitro method where a target DNA molecule has been modified, there is no disclosure in the specification or the art at the time of the invention regarding a method to successfully edit a target DNA molecule in vivo with the recited fusion protein, including in a human being. The specification is silent as to how to deliver a fusion as recited to a multicellular organism and successfully obtain the desired modification. Therefore, in view of the fact that the specification only discloses an in vitro method to modify an A to a G with a fusion protein that comprises SEQ ID NO: 407 and a Cas9 nickase, and the lack of description regarding the successful delivery of a fusion protein to a multicellular organism and the editing of a target DNA in said multicellular organism, where an A is edited to any base, one of skill in the art would not recognize from the disclosure that Applicant was in possession of the claimed invention. Claims 1-19 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for an in vitro method to modify a target DNA molecule, wherein said method comprises contacting a target DNA molecule with (i) a fusion protein that comprises an adenine deaminase that comprises SEQ ID NO: 407 and a Cas9 nickase that comprises one of SEQ ID NO: 42, 52, 53, 55-59, 61, 397 or 398, and (ii) a guide RNA that is able to hybridize to the target DNA molecule and binds to the fusion protein to comprise a complex, wherein said contacting results in the replacement of an A in the target DNA molecule with a G, thus modifying said target DNA molecule, does not reasonably provide enablement for an in vivo, in vitro or ex vitro method to modify a target DNA molecule, wherein said method comprises contacting a target DNA molecule with (i) a fusion protein that comprises an adenine deaminase that comprises SEQ ID NO: 407 and a Cas9 nickase that comprises one of SEQ ID NO: 42, 52, 53, 55-59, 61, 397 or 398, and (ii) a guide RNA that is able to hybridize to the target DNA molecule and binds to the fusion protein to comprise a complex, wherein said contacting results in the replacement of an A in the target DNA molecule with any base, thus modifying said target DNA molecule. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. Factors to be considered in determining whether undue experimentation is required are summarized in In re Wands (858 F.2d 731, 737, 8 USPQ2nd 1400 (Fed. Cir. 1988)) as follows: 1) quantity of experimentation necessary, 2) the amount of direction or guidance presented, 3) the presence and absence of working examples, 4) the nature of the invention, 5) the state of prior art, 6) the relative skill of those in the art, 7) the predictability or unpredictability of the art, and 8) the breadth of the claims. The factors which have led the Examiner to conclude that the specification fails to teach how to make and/or use the claimed invention without undue experimentation, are addressed in detail below. The breadth of the claims. Claims 1-19 broadly encompass in vivo, in vitro or ex vitro method to modify a target DNA molecule, wherein said method comprises contacting a target DNA molecule with (i) a fusion protein that comprises an adenine deaminase that comprises SEQ ID NO: 407 and a Cas9 nickase that comprises one of SEQ ID NO: 42, 52, 53, 55-59, 61, 397 or 398, and (ii) a guide RNA that is able to hybridize to the target DNA molecule and binds to the fusion protein to comprise a complex, wherein said contacting results in the replacement of an A in the target DNA molecule with any base and not just G, thus modifying said target DNA molecule. The claims also encompass modifying a target DNA in a multicellular organism, like a human being. See Claim Rejections - 35 USC § 112(b) or Second Paragraph (pre-AIA ) for claim interpretation. Therefore, in its broadest reasonable interpretation, the claims encompass methods to generate transgenic multicellular organisms and gene therapy. The enablement provided is not commensurate in scope with the claim due to the extremely large number of transgenic multicellular organisms, including humans, that the specification fails to teach how to generate or how to use, as well as the lack of information as to how to practice the claimed method in humans to obtain the desired gene modification, and the structural features required in a variant having at least 90% sequence identity to the polypeptide of SEQ ID NO: 407 such that an A can be edited to any base. In the instant case, the specification enables an in vitro method to modify a target DNA molecule, wherein said method comprises contacting a target DNA molecule with (i) a fusion protein that comprises an adenine deaminase that comprises SEQ ID NO: 407 and a Cas9 nickase that comprises one of SEQ ID NO: 42, 52, 53, 55-59, 61, 397 or 398, and (ii) a guide RNA that is able to hybridize to the target DNA molecule and binds to the fusion protein to comprise a complex, wherein said contacting results in the replacement of an A in the target DNA molecule with a G, thus modifying said target DNA molecule The amount of direction or guidance presented and the existence of working examples. While the specification discloses that the protein of SEQ ID NO: 407 can edit an A to a G, the specification is silent with regard to those modifications that can be made to the protein of SEQ ID NO: 407 to obtain a variant having at least 90% sequence identity to the polypeptide of SEQ ID NO: 407 which is able to edit an A to C or T. In addition, while the specification discloses an in vitro method where a target DNA molecule has been modified with a fusion protein that comprises the protein of SEQ ID NO: 407 and a Cas9 nickase, wherein the modification is the substitution of an A to a G, the specification is silent with regard to how to successfully edit a target DNA molecule in vivo with the recited fusion protein, including in a human being. There are no working examples or specific methods disclosed showing a transgenic animal where the recited fusion protein has been able to make a genetic modification of a target DNA in said animal, or the successful modification of a target nucleic acid after delivery of such fusion protein to a subject without unspecific non-targeted modifications. Also, there are no working examples or specific methods disclosed showing how to deliver the recited fusion protein to any human tissue so that the fusion protein can be used for therapeutic purposes. The specification is silent as to how to deliver a fusion as recited to a multicellular organism and successfully obtain the desired modification. The state of prior art, the relative skill of those in the art, and the predictability or unpredictability of the art. The amino acid sequence of a protein determines the function of such protein. Neither the specification nor the art provide a correlation between structure and function such that one of skill in the art can envision the structure of an adenine deaminase or a variant of the polypeptide of SEQ ID NO: 407 having at least 90% sequence identity to the polypeptide of SEQ ID NO: 407 that can have the ability to edit an A to any base. The art, as evidenced by Pulman et al. (Molecular Therapy: Nucleic Acids, 35(4):1-15, 2024), teaches that while a limited number of methods to deliver a complex of a Cas9, an adenine-base editor and a guide RNA are known in the art, delivery efficacy in vivo can be hampered by intracellular barriers. Pulman et al. teach that while a complex of a Cas9, an adenine-base editor and a guide RNA was delivered to retinal cells, editing rates vary based on the efficacy of the guide RNA, and the specific location edited within the target gene (Abstract). Pulman et al. teach that the concentration of the Cas9 complex can lead to toxicity and that there is a need to improve delivery efficiency for potential therapeutic applications in the future (Abstract). Pulman et al. teach that editing efficiency is dependent on the dose of the complex, the sequence of the guide RNA and the expression level of the target gene in a given cell type, and that the delivery efficacy is hampered by intracellular barriers such as nuclear entry and the accessibility of the target gene within the genome once the complex reaches the nucleus (page 2, left column). Pulman et al. teach that while selecting the right design tool for a guide RNA and experimental workflow would allow a successful gene editing experiment in vitro, in vivo gene editing is tissue and cell type specific, requiring additional experimentation to perform relevant optimization (page 10, right column). Therefore, the state of the art after the filing date of the instant application clearly teaches the unpredictability of practicing an in vivo method as claimed. The quantity of experimentation required to practice the claimed invention based on the teachings of the specification. While methods of isolating/making polypeptides and enzymatic assays were known in the art at the time of the invention, it was not routine in the art to screen by a trial and error process for any number of proteins and determine which ones can edit an A to any base. In the absence of (a) a rational and predictable scheme for identifying which proteins are more likely to have the desired activity, and/or (b) a correlation between structure and activity, one of skill in the art would have to test an essentially infinite number of proteins to determine which proteins have the desired activity. In addition, given the teachings of the art regarding the limitations associated with delivering a fusion protein to a multicellular organism so that it can reach the target DNA, the unpredictability of observing base editing of any target gene in any tissue, and in view of the lack of guidance provided by the specification, it would have required undue experimentation to practice the full scope of the claimed method. Conclusion No claim is in condition for allowance. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Applicant is advised that any Internet email communication by the Examiner has to be authorized by Applicant in written form. See MPEP § 502.03 (II). Without a written authorization by Applicant in place, the USPTO will not respond via Internet email to any Internet correspondence which contains information subject to the confidentiality requirement as set forth in 35 U.S.C. 122. Sample written authorization language can be found in MPEP § 502.03 (II). An Authorization for Internet Communications in a Patent Application or Request to Withdraw Authorization for Internet Communications form (SB/439) can be found at https://www.uspto.gov/patent/forms/ forms-patent-applications-filed-or-after-september-16-2012, which can be electronically filed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DELIA M RAMIREZ, Ph.D., whose telephone number is (571) 272-0938. The examiner can normally be reached on Monday-Friday from 8:30 AM to 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert B. Mondesi, can be reached at (408) 918-7584. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. /DELIA M RAMIREZ/Primary Examiner, Art Unit 1652 DR October 28, 2026
Read full office action

Prosecution Timeline

Nov 21, 2024
Application Filed
Oct 30, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778133
METHODS FOR PROTECTING ANIMALS FROM PATHOGENS USING EXOSPORIUM FRAGMENTS
9y 7m to grant Granted Nov 03, 2026
Patent 12716081
MUTANT OF CORYNEBACTERIUM GLUTAMICUM WITH ENHANCED L-CITRULLINE PRODUCTIVITY AND METHOD FOR PREPARING L-CITRULLINE USING THE SAME
2y 10m to grant Granted Aug 25, 2026
Patent 12698515
GENETICALLY ENGINEERED BACTERIUM USING GLUCOSE AS SUBSTRATE FOR DE NOVO SYNTHESIS OF VANILLIN AND APPLICATION THEREOF
2y 4m to grant Granted Aug 04, 2026
Patent 12698492
ISOLATED CAS13 PROTEIN AND USE THEREOF
2y 3m to grant Granted Aug 04, 2026
Patent 12668785
COMBINATION TREATMENT
2y 11m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+56.3%)
Low
PTA Risk
Based on 857 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month